Elizabeth Fox, MD, MS

faculty photo
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
Division of Oncology
CTRB4016
3501 Civic Center Blvd
Philadelphia, PA 19104
Education:
BS (Laboratory Sciences)
Northeastern University, College of Pharmacy & Allied Health, Boston, MA, 1988.
MD
Pennsylvania State University College of Medicine Hershey, PA, 1993.
MS (Clinical Research)
Duke University College of Medicine Durham, NC, 2006.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Flynn, A; Fox E: Evolving paradigms for new agent development in pediatric oncology. Current Opinions Pediatrics 30(1): 10-16, Feb 2018.

Fox, E; Levin, K; Zhu, Y; Segers, B; Blalmuth, N; Womer, RW; Bagatell, R; Balis, F.: Pantoprazole, an inhibitor of the organic cation transporter 2, does not ameliorate cisplatin-related ototoxicity or nephrotoxicity in children and adolescents with newly diagnosed osteosarcoma treated with methotrexate, doxorubicin, and cisplatin. Oncologist Page: doi 10.1634/theoncologist.2018-0037, Feb 2018.

Kraft, IL; Akshintala, S; Zhu, Y; Lei, H; Derse-Anthony, C; Dombi, E; Steinberg, SM; Lodish, M; Wagerspack SG; Kapustina, O; Fox, E; Balis, FM; Merino, MJ: Meltzer, PS; Glod, JW; Shern JF; Widemann BC.: Outcomes of children and adolescents with advanced hereditary medullary thyroid carcinoma treated with vandetanib. Clinical Cancer Research 24(4): 753-65, Feb 2018.

Norris, RE; Fox, E; Reid, JM; Ralya A; Lei XW; Minard C; Weigel BJ.: Phase 1 trial of ontuximab (MORab-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatric Blood and Cancer Page: doi: 10.1002/pbc.26944. Jan 2018.

Pradhan KR, Berg SL, Liu X, Minard GC, Croop J, Reid JM, Fox E, Weigel BJ : A Dose Escalation and Toxicity Study Using Pre-determined Target Concentration of Ramucirumab, an Anti-angiogenic Agent, in Children with Recurrent/ Refractory Solid Tumors: A Children’s Oncology Group/ Phase-1 Consortium Trial (ADVL1416) American Association for Cancer Research, Chicago, IL 2018.

London LB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR.: Historical time-to-progression (TTP) and progression-free survival (PFS) in relapsed/refractory neuroblastoma modern-era (2002-14) patients from Children’s Oncology Group (COG) early-phase trials. Cancer 123(24): 4914-4923, Dec 2017 Notes: Accepted 6/14/17.

Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. : Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197) in Children with Relapsed or Refractory Solid Tumors (ADVL1111): A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial. Ped Blood Cancer 64(11): doi: 10.1002, Nov 2017.

Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E: Dosing Anticancer Drugs in Infants: Current Approach and Recommendations from the Children’s Oncology Group’s Chemotherapy Standardization Task Force Pediatric Blood and Cancer 64(11): doi: 10.1002, Nov 2017.

Mosse YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson PC, Blaney SB, Weigel BJ.: Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A Children's Oncology Group Study. J Clin Oncol 35(28): 3215-3221, Oct 2017.

Leary SES, Park JR, Reid JM, Ralya AT, Baruchel S, Wu B, Roberts TPL Liu X, Minard CG, Fox E, Weigel BJ, Blaney S.: Pediatric phase 1 trial and pharmacokinetic study of trebananib in relapsed solid tumors ADVl1115: A Children's Oncology Group phase 1 consortium report. Clinical Cancer Research 23(20): 6062-6069, Oct 2017.

back to top
Last updated: 04/05/2018
The Trustees of the University of Pennsylvania